Frankfurt - Delayed Quote EUR

Zevra Therapeutics, Inc. (1GDA.F)

Compare
7.65
-0.10
(-1.29%)
At close: January 24 at 8:01:10 AM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
24,489.00
--
10,161.00
28,650.00
13,288.00
Cost of Revenue
8,050.00
--
222.00
2,059.00
1,305.00
Gross Profit
16,439.00
--
9,939.00
26,591.00
11,983.00
Operating Expense
103,183.00
--
34,841.00
18,862.00
16,764.00
Operating Income
-86,744.00
--
-24,902.00
7,729.00
-4,781.00
Net Non Operating Interest Income Expense
-3,455.00
--
1,178.00
-115.00
-7,001.00
Other Income Expense
535.00
--
-3,081.00
-16,135.00
-1,012.00
Pretax Income
-89,664.00
--
-26,805.00
-8,521.00
-12,794.00
Tax Provision
--
--
-33.00
34.00
-34.00
Net Income Common Stockholders
-89,664.00
--
-26,772.00
-62,897.00
-12,760.00
Diluted NI Available to Com Stockholders
-89,664.00
--
-26,772.00
-62,897.00
-12,760.00
Basic EPS
-2.13
-1.30
-1.20
-2.11
-3.21
Diluted EPS
-2.13
-1.30
-1.20
-2.11
-3.21
Basic Average Shares
42,562.29
35,452.46
34,488.80
29,766.35
3,980.98
Diluted Average Shares
42,562.29
35,452.46
34,488.80
29,766.35
3,980.98
Total Operating Income as Reported
-86,744.00
--
-42,565.00
7,729.00
-5,609.00
Total Expenses
111,233.00
--
35,063.00
20,921.00
18,069.00
Net Income from Continuing & Discontinued Operation
-89,664.00
--
-26,772.00
-8,555.00
-12,760.00
Normalized Income
-90,199.00
--
-23,694.70
3,223.55
-11,750.63
Interest Income
2,458.00
--
1,513.00
261.00
89.00
Interest Expense
5,913.00
--
335.00
376.00
7,090.00
Net Interest Income
-3,455.00
--
1,178.00
-115.00
-7,001.00
EBIT
-83,751.00
--
-26,470.00
-8,145.00
-5,704.00
EBITDA
-78,223.00
--
-25,526.00
-7,888.00
-5,431.00
Reconciled Cost of Revenue
8,050.00
--
222.00
2,059.00
1,305.00
Reconciled Depreciation
5,528.00
--
944.00
257.00
273.00
Net Income from Continuing Operation Net Minority Interest
-89,664.00
--
-26,772.00
-8,555.00
-12,760.00
Total Unusual Items Excluding Goodwill
535.00
--
-3,081.00
-16,135.00
-1,012.00
Total Unusual Items
535.00
--
-3,081.00
-16,135.00
-1,012.00
Normalized EBITDA
-78,758.00
--
-22,445.00
8,247.00
-4,419.00
Tax Rate for Calcs
--
--
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
-3.70
-4,356.45
-2.63
12/31/2020 - 6/22/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

2Q5.BE Enochian BioSciences Inc
0.8480
-12.94%
 
HQ1.MU Oruka Therapeutics Inc. R
12.20
0.00%
 
BT3.BE Lineage Cell Therapeutics Inc
0.5850
-7.87%
 
PH4.F CStone Pharmaceuticals
0.2860
0.00%
 
ORN.F Oryzon Genomics S.A.
1.4100
-3.16%
 
4FR.BE Faron Pharmaceuticals Oy
2.2100
+1.38%
 
ADOCY Adocia SA
11.80
0.00%
 
A89.MU Adocia SAS A
6.04
+1.17%
 
ANNX.ST Annexin Pharmaceuticals AB (publ)
0.4850
-1.02%
 
25I.F ImmuPharma plc
0.0225
-18.18%